Whole blood transcriptional variations between responders and non‐responders in asthma patients receiving omalizumab-Reference-Cited by-同舟云学术

Whole blood transcriptional variations between responders and non‐responders in asthma patients receiving omalizumab

Published:2020-07-15 Issue: Volume: Page:
ISSN:0954-7894
Container-title:Clinical & Experimental Allergy
language:en
Short-container-title:Clin Exp Allergy

Author:

Upchurch Katherine¹^ORCID,Wiest Matthew¹²,Cardenas Jacob³,Skinner Jason³,Nattami Durgha³,Lanier Bobby⁴,Millard Mark⁵,Joo HyeMee¹²,Turner Jacob⁶,Oh SangKon¹²^ORCID

Affiliation:

1. Baylor UniversityInstitute for Biomedical Studies Waco TX USA

2. Department of ImmunologyMayo Clinic Scottsdale AZ USA

3. Baylor Institute for Immunology Research Dallas TX USA

4. North Texas Institute for Clinical Trials Ft Worth TX USA

5. Martha Foster Lung Care CenterBaylor University Medical Center Dallas TX USA

6. Department of Mathematics and StatisticsStephen F. Austin State University Nacogdoches TX USA

Funder

American Asthma Foundation

Genentech

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cea.13671

Reference74 articles.

1. The anti‐inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation;Holgate S;J Allergy Clin Immunol,2005

2. Humanization of an antibody directed against IgE;Presta LG;J Immunol,1993

3. The binding site on human immunoglobulin E for its high affinity receptor;Presta L;J Biol Chem,1994

4. Anti‐IgE antibodies for the treatment of IgE‐mediated allergic diseases;Chang TW;Adv Immunol,2007

5. Fc epsilon receptor I on dendritic cells delivers IgE‐bound multivalent antigens into a cathepsin S‐dependent pathway of MHC class II presentation;Maurer D;J Immunol,1998

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A robust mRNA signature obtained via recursive ensemble feature selection predicts the responsiveness of omalizumab in moderate‐to‐severe asthma;Clinical and Translational Allergy;2023-11

2. IgE glycosylation is essential for the function of omalizumab;Allergy;2023-04-28

3. Definitions of non-response and response to biological therapy for severe asthma: a systematic review;ERJ Open Research;2023-01-26

4. Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives;Frontiers in Immunology;2022-12-06

5. Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis;Expert Review of Respiratory Medicine;2022-06-23